(IVZ) - Overview
Sector: Financial Services | Industry: Asset Management | Exchange: NYSE (USA) | Market Cap: 12.022m USD | Total Return: 78.7% in 12m
Mutual Funds, ETFs, Private Funds, Separate Accounts
Total Rating 45
Safety 14
Buy Signal -0.45
Asset Management
Industry Rotation: -5.1
Industry Rotation: -5.1
Market Cap:
12.0B
Avg Turnover: 134M
Avg Turnover: 134M
Risk 3d forecast
Volatility36.0%
VaR 5th Pctl6.21%
VaR vs Median4.78%
Reward TTM
Sharpe Ratio1.72
Rel. Str. IBD77.5
Rel. Str. Peer Group84.8
Character TTM
Beta1.708
Beta Downside1.808
Hurst Exponent0.379
Drawdowns 3y
Max DD36.52%
CAGR/Max DD0.73
CAGR/Mean DD2.59
EPS (Earnings per Share)
EPS CAGR: 10.65%
EPS Trend: 71.8%
EPS Trend: 71.8%
Last SUE: -0.11
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 3.55%
Rev. Trend: 78.5%
Rev. Trend: 78.5%
Last SUE: 0.80
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: IVZ
Invesco Ltd. (IVZ) is a global investment management firm serving a diverse client base that includes retail investors, institutional entities, and sovereign wealth funds. The company manages a broad array of products, including exchange-traded funds (ETFs), mutual funds, and private funds, covering asset classes such as equities, fixed income, commodities, and currencies. Invesco utilizes quantitative analysis and diverse investment strategies, including global macro and long/short approaches, to manage portfolios across various market capitalizations and credit qualities.
The asset management industry operates primarily on a fee-based model, where revenue is generated as a percentage of assets under management (AUM). Invescos business model is characterized by its significant presence in the passive investment space through its PowerShares ETF lineup, which competes on the basis of liquidity and expense ratios. As market conditions shift, evaluating the firm’s valuation metrics on ValueRay can provide deeper insights into its historical performance. Founded in 1935 and headquartered in Atlanta, the firm maintains a global operational footprint across North America, Europe, Africa, and Asia.
- Total assets under management fluctuations drive management fee revenue and margins
- Invesco QQQ performance and ETF inflows dictate passive asset market share
- Global interest rate shifts impact fixed income demand and yield products
- Operating leverage depends on successful cost containment and technology integration efforts
- Shift toward low-fee passive products pressures overall net revenue margins
Piotroski VR‑10 (Strict)
4.5
| Net Income: -243.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.85 > 1.0 |
| NWC/Revenue: -10.68% < 20% (prev 25.96%; Δ -36.63% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.82b > Net Income -243.4m |
| Net Debt (9.73b) to EBITDA (1.30b): 7.48 < 3 |
| Current Ratio: 0.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (453.7m) vs 12m ago -0.07% < -2% |
| Gross Margin: 50.68% > 18% (prev 0.34%; Δ 5.03k% > 0.5%) |
| Asset Turnover: 23.98% > 50% (prev 21.75%; Δ 2.23% > 0%) |
| Interest Coverage Ratio: -9.66 > 6 (EBITDA TTM 1.30b / Interest Expense TTM 93.7m) |
Altman Z''
0.75
| A: -0.03 (Total Current Assets 806.9m - Total Current Liabilities 1.51b) / Total Assets 26.83b |
| B: 0.22 (Retained Earnings 6.02b / Total Assets 26.83b) |
| C: -0.03 (EBIT TTM -904.7m / Avg Total Assets 27.49b) |
| D: 0.39 (Book Value of Equity 5.34b / Total Liabilities 13.57b) |
| Altman-Z'' Score: 0.75 = B |
Beneish M
1.00
| DSRI: 7.35 (Receivables 8.96b/1.13b, Revenue 6.59b/6.12b) |
| GMI: 0.67 (GM 50.68% / 34.05%) |
| AQI: 1.09 (AQ_t 0.96 / AQ_t-1 0.88) |
| SGI: 1.08 (Revenue 6.59b / 6.12b) |
| TATA: -0.08 (NI -243.4m - CFO 1.82b) / TA 26.83b) |
| Beneish M-Score: 1.94 (Cap -4..+1) = D |
What is the price of IVZ shares?
As of May 20, 2026, the stock is trading at USD 26.47 with a total of 3,751,992 shares traded.
Over the past week, the price has changed by -6.00%, over one month by +6.92%, over three months by +1.20% and over the past year by +78.71%.
Over the past week, the price has changed by -6.00%, over one month by +6.92%, over three months by +1.20% and over the past year by +78.71%.
Is IVZ a buy, sell or hold?
has received a consensus analysts rating of 3.07.
Therefor, it is recommend to hold IVZ.
- StrongBuy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the IVZ price?
| Analysts Target Price | 29.1 | 10.1% |
(IVZ) - Fundamental Data Overview
as of 18 May 2026
P/E Forward = 10.3734 P/S = 1.8236
P/B = 1.2551
P/EG = 0.3832
Revenue TTM = 6.59b USD
EBIT TTM = -904.7m USD
EBITDA TTM = 1.30b USD
Long Term Debt = 9.44b USD (from longTermDebt, last quarter)
Short Term Debt = 66.6m USD (from shortTermDebt, last fiscal year)
Debt = 10.54b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.73b USD (from netDebt column, last quarter)
Enterprise Value = 21.76b USD (12.02b + Debt 10.54b - CCE 806.9m)
Interest Coverage Ratio = -9.66 (Ebit TTM -904.7m / Interest Expense TTM 93.7m)
EV/FCF = 12.07x (Enterprise Value 21.76b / FCF TTM 1.80b)
FCF Yield = 8.29% (FCF TTM 1.80b / Enterprise Value 21.76b)
FCF Margin = 27.34% (FCF TTM 1.80b / Revenue TTM 6.59b)
Net Margin = -3.69% (Net Income TTM -243.4m / Revenue TTM 6.59b)
Gross Margin = 50.68% ((Revenue TTM 6.59b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 65.53% (prev 66.96%)
Tobins Q-Ratio = 0.81 (Enterprise Value 21.76b / Total Assets 26.83b)
Interest Expense / Debt = 0.23% (Interest Expense 24.3m / Debt 10.54b)
Taxrate = 27.02% (81.1m / 300.2m)
NOPAT = -660.3m (EBIT -904.7m * (1 - 27.02%)) [loss with tax shield]
Current Ratio = 0.53 (Total Current Assets 806.9m / Total Current Liabilities 1.51b)
Debt / Equity = 0.86 (Debt 10.54b / totalStockholderEquity, last quarter 12.26b)
Debt / EBITDA = 7.48 (Net Debt 9.73b / EBITDA 1.30b)
Debt / FCF = 5.40 (Net Debt 9.73b / FCF TTM 1.80b)
Total Stockholder Equity = 13.09b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.89% (Net Income -243.4m / Total Assets 26.83b)
RoE = -1.86% (Net Income TTM -243.4m / Total Stockholder Equity 13.09b)
RoCE = -4.02% (EBIT -904.7m / Capital Employed (Equity 13.09b + L.T.Debt 9.44b))
RoIC = -4.15% (negative operating profit) (NOPAT -660.3m / Invested Capital 15.91b)
WACC = 6.47% (E(12.02b)/V(22.56b) * Re(11.99%) + D(10.54b)/V(22.56b) * Rd(0.23%) * (1-Tc(0.27)))
Discount Rate = 11.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -8.99 | Cagr: 0.06%
[DCF] Terminal Value 86.78% ; FCFF base≈1.52b ; Y1≈1.87b ; Y5≈3.19b
[DCF] Fair Price = 158.3 (EV 79.89b - Net Debt 9.73b = Equity 70.15b / Shares 443.3m; r=6.47% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 71.76 | EPS CAGR: 10.65% | SUE: -0.11 | # QB: 0
Revenue Correlation: 78.47 | Revenue CAGR: 3.55% | SUE: 0.80 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.61 | Chg30d=-3.06% | Revisions=-50% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.67 | Chg30d=+2.46% | Revisions=-9% | Analysts=9
EPS current Year (2026-12-31): EPS=2.59 | Chg30d=+0.35% | Revisions=-47% | GrowthEPS=+27.4% | GrowthRev=+11.2%
EPS next Year (2027-12-31): EPS=2.97 | Chg30d=+2.39% | Revisions=-38% | GrowthEPS=+14.8% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -50%